BTK inhibitor

DRUG6 trials

Sponsors

Ruijin Hospital, Ascentage Pharma Group Inc., Fei Li, The First Affiliated Hospital with Nanjing Medical University, Peking University People's Hospital

Conditions

CLLCLL/SLLDiffuse Large B Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

Phase 1

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

RecruitingNCT06675123

City of Hope Medical CenterRecurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

Start: 2026-10-01End: 2028-03-08Target: 10Updated: 2026-08-05

Phase 2

A Combination Study of CAR-T Therapy in r/r B-NHL

Ruijin HospitalDiffuse Large B Cell Lymphoma

Start: 2023-06-10End: 2024-08-30Target: 48Updated: 2023-08-01

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

Not yet recruitingNCT06476899

Start: 2024-07-24End: 2026-12-26Target: 60Updated: 2024-06-27

Phase 3

Global Trial in APG2575 for Patients With CLL/SLL

RecruitingNCT06104566

Ascentage Pharma Group Inc.CLL/SLL

Start: 2023-12-20End: 2027-10-31Target: 400Updated: 2026-06-18

Unknown Phase

Current Status of BTKi Treatment for CLL/SLL in China

RecruitingNCT06508684

The First Affiliated Hospital with Nanjing Medical UniversityCLL/SLL

Start: 2024-07-13End: 2025-07-12Target: 1000Updated: 2024-07-18

The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

Not yet recruitingNCT06557304

Peking University People's HospitalCLL

Start: 2024-09-01End: 2027-12-30Target: 1000Updated: 2024-08-21

Related Papers

A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.

Journal of Clinical Oncology2026-05-28

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Blood2024-11-058 citations